^
Association details:
| Biomarker: | KRAS G12V |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + onvansertib (PCM-075) (PLK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC
Published date:
04/12/2021
Excerpt:
Patients enrolled in the ongoing Phase 1b/2 trial receive onvansertib in combination with standard-of-care FOLFIRI and Avastin® (bevacizumab)....Clinical responses were observed across different KRAS mutations, including the 3 most common in colorectal cancer (G12D, G12V, G13D)
Secondary therapy:
FOLFIRI
Trial ID:
